{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:07:52Z","timestamp":1785330472925,"version":"3.55.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate the efficacy of bDMARDs in patients with RA with RF\/ACPA compared with patients without these autoantibodies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Previous systematic literature reviews performed by EULAR RA management task forces were searched for qualifying RCTs. RCTs investigating the efficacy of bDMARDs and including both autoantibody-positive (\u226480% of total population) and -negative RA patients were eligible. For trials comparing bDMARD+csDMARD vs csDMARD, relative risks (RR) comparing two groups (RF+ vs RF-, ACPA+ vs ACPA-) were calculated for efficacy outcomes for each arm. Subsequently, relative risk ratios (RRRs) were computed, as the ratio of RR of the bDMARD-arm and the RR from the non-bDMARD-arm. Pooled effects were obtained with random effect meta-analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data from 28 eligible RCTs were analysed, pooling 23 studies in three subgroups: six including csDMARD-naive patients, 14 csDMARD-IR and three TNFi-IR patients. In csDMARD-naive and csDMARD-IR patients, seropositivity was not associated with a better response to bDMARDs: pooled 6-month ACR20 RRRs 1.02 (0.88\u20131.18) and 1.09 (0.90\u20131.32), respectively. Other outcomes showed no difference between groups either. In TNFi-IR patients, based on three trials, the 6-month ACR20 RRR was 2.28 (1.31\u20133.95), favoring efficacy in seropositive patients. Other outcomes mostly showed no significant difference between the groups. Based on the mode of action, efficacy was comparable between RF-positive and RF-negative patients for both TNFi and non-TNFi treatment and also for the individual bDMARDs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The effect of bDMARDs is generally comparable in patients with and without RF\/ACPA, regardless of the patient population, the mechanism of action or individual drug used.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae113","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T11:54:07Z","timestamp":1708170847000},"page":"548-560","source":"Crossref","is-referenced-by-count":10,"title":["The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4965-9274","authenticated-orcid":false,"given":"Kaoru","family":"Takase-Minegishi","sequence":"first","affiliation":[{"name":"Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine , Yokohama,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9108-9212","authenticated-orcid":false,"given":"Stefan","family":"B\u00f6hringer","sequence":"additional","affiliation":[{"name":"Department of Biomedical Data Sciences, Leiden University Medical Center , Leiden,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4944-7922","authenticated-orcid":false,"given":"Jackie L","family":"Nam","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital , Leeds,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[{"name":"CIRI\/Rheumatology and Fraunhofer Institute, Translational Medicine and Pharmacology ITMP, Goethe University , Frankfurt,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saedis","family":"Saevarsdottir","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]},{"name":"Faculty of Medicine, School of Health Sciences, University of Iceland , Reykjavik,","place":["Iceland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Detert","sequence":"additional","affiliation":[{"name":"Rheumatological-Immunological Medical Practice , Templin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1568-9045","authenticated-orcid":false,"given":"Marjatta","family":"Leirisalo-Repo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Helsinki and Helsinki University Hospital , Helsinki,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Landew\u00e9","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center , Amsterdam, The","place":["Netherlands"]},{"name":"Department of Rheumatology, Zuyderland Medical Center , Heerlen,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden,","place":["the Netherlands"]},{"name":"Department of Rheumatology, Zuyderland Medical Center , Heerlen,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8121-5879","authenticated-orcid":false,"given":"Diane","family":"van der Woude","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leiden University Medical Center , Leiden,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"2025032905210995700_keae113-B1","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1136\/ard.2004.033571","article-title":"Longitudinal analysis of citrullinated protein\/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression","volume":"64","author":"R\u00f6nnelid","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025032905210995700_keae113-B2","doi-asserted-by":"crossref","first-page":"R949","DOI":"10.1186\/ar1767","article-title":"Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis","volume":"7","author":"van der Helm-van Mil","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"2025032905210995700_keae113-B3","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/art.24661","article-title":"Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts","volume":"60","author":"van der Woude","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2025032905210995700_keae113-B4","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41584-022-00786-4","article-title":"From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis","volume":"18","author":"Scherer","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025032905210995700_keae113-B5","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/ard.2010.148759","article-title":"Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries","volume":"70","author":"Chatzidionysiou","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2025032905210995700_keae113-B6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3899\/jrheum.110610","article-title":"Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register","volume":"39","author":"Soliman","year":"2012","journal-title":"J Rheumatol"},{"key":"2025032905210995700_keae113-B7","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.39595","article-title":"Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the pan-European registry analysis","volume":"68","author":"Gottenberg","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025032905210995700_keae113-B8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3899\/jrheum.170007","article-title":"Effect of anticitrullinated protein antibody status on response to abatacept or antitumor necrosis factor-\u03b1 therapy in patients with rheumatoid arthritis: a US National Observational Study","volume":"45","author":"Harrold","year":"2018","journal-title":"J Rheumatol"},{"key":"2025032905210995700_keae113-B9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40744-019-0149-3","article-title":"Comparative effectiveness of abatacept versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis who are anti-Ccp positive in the United States Corrona Registry","volume":"6","author":"Harrold","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2025032905210995700_keae113-B10","doi-asserted-by":"crossref","first-page":"19717","DOI":"10.1038\/s41598-020-76842-4","article-title":"A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients","volume":"10","author":"Kida","year":"2020","journal-title":"Sci Rep"},{"key":"2025032905210995700_keae113-B11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40744-021-00401-0","article-title":"Association between baseline anti-cyclic citrullinated peptide antibodies and 6-month clinical response following abatacept or TNF inhibitor treatment: a real-world analysis of biologic-experienced patients with RA","volume":"9","author":"Harrold","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2025032905210995700_keae113-B12","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","article-title":"The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries","volume":"60","author":"Courvoisier","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025032905210995700_keae113-B13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","article-title":"Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis","volume":"72","author":"Isaacs","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025032905210995700_keae113-B14","doi-asserted-by":"crossref","first-page":"e89442","DOI":"10.1371\/journal.pone.0089442","article-title":"The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNF\u03b1 agent treatment in patients with rheumatoid arthritis: a meta-analysis","volume":"9","author":"Lv","year":"2014","journal-title":"PloS One"},{"key":"2025032905210995700_keae113-B15","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/ard.2009.126573","article-title":"Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA","volume":"69","author":"Nam","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025032905210995700_keae113-B16","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025032905210995700_keae113-B17","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"76","author":"Nam","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025032905210995700_keae113-B18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2025032905210995700_keae113-B19","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025032905210995700_keae113-B20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/annrheumdis-2017-211375","article-title":"Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study","volume":"77","author":"Akdemir","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025032905210995700_keae113-B21"},{"key":"2025032905210995700_keae113-B22"},{"key":"2025032905210995700_keae113-B23"},{"key":"2025032905210995700_keae113-B24","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr.21649","article-title":"Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice","volume":"64","author":"Anderson","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025032905210995700_keae113-B25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2025032905210995700_keae113-B26","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"2025032905210995700_keae113-B27","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2025032905210995700_keae113-B28","first-page":"129","article-title":"A note on the \u03b4-method for finding variance formulae","volume":"1","author":"Dorfman","year":"1938","journal-title":"Biom Bull"},{"key":"2025032905210995700_keae113-B29","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2025032905210995700_keae113-B30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/art.30233","article-title":"B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study","volume":"63","author":"Sellam","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025032905210995700_keae113-B31","first-page":"442","article-title":"Autoantibody-positive rheumatoid arthritis patients have enhanced clinical response to rituximab when compared with seronegative patients","volume":"68","author":"Isaacs","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025032905210995700_keae113-B32","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/art.30596","article-title":"Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment","volume":"63","author":"Lal","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025032905210995700_keae113-B33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"Sokolove","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025032905210995700_keae113-B34","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/ard-2022-223349","article-title":"Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025032905210995700_keae113-B35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.39944","article-title":"Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025032905210995700_keae113-B36","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0140-6736(17)30401-4","article-title":"Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study","volume":"389","author":"Aletaha","year":"2017","journal-title":"Lancet"},{"key":"2025032905210995700_keae113-B37","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1136\/ard-2022-222630","article-title":"Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study","volume":"81","author":"Feist","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae113\/57142588\/keae113.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/2\/548\/57142588\/keae113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/2\/548\/57142588\/keae113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T03:29:51Z","timestamp":1743391791000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/2\/548\/7609797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,16]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae113","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,2,16]]}}}